Home / Stocks / CLS

Celestica (CLS, Contract electronics makers) Stock Valuation & Fair Value

Significantly overvalued

Celestica (CLS, Contract electronics makers) trades at a current P/E of 19.2, about 52% above its historical normal valuation, with a forward growth estimate of 65.9% and a PEG of 0.29. Analysts' one-year estimates have been hit 9% of the time. Priced at its historical normal P/E of 12.6 on the same blended earnings, the 2026-11-06 close of $206.68 corresponds to about $136 a share. This is a valuation reference, not a price target.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

Current P/E
19.2
Normal P/E
12.6
PEG
0.29
Fwd growth
65.9%
Div yield
0.0%
RSI (14)
29.7
Oversold
Technical context
  • Price $206.68 at the Nov 6 close, 26.3% below the 20-day average ($280.51) and 34.9% below the 50-day ($317.26).
  • RSI (14) at 29.7.
  • 52-week range $205.64 to $472.40: the price is 56.2% below the high and 0.5% above the low.

The Street vs SeerForecast

Wall Street's mean price target for CLS is $464.78 across 18 analysts, 124.9% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from favorable on our tests (2026-09-19) to significantly overvalued (2026-11-02). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

Current P/E and rating by weekCurrent P/E moved from 33.8 to 25.1 between 2026-09-18 and 2026-10-30, against a normal P/E of 12.6, with 1 rating change over 7 recorded weeks.2026-09-18: P/E 33.8, Favorable on our tests, recalculated for the week of 2026-09-192026-09-18: P/E 33.8, Favorable on our tests, recorded live 2026-09-212026-09-25: P/E 37.1, Favorable on our tests, recalculated for the week of 2026-09-262026-09-25: P/E 37.1, Significantly overvalued, recorded live 2026-09-282026-10-02: P/E 39.5, Significantly overvalued, recalculated for the week of 2026-10-032026-10-02: P/E 39.5, Significantly overvalued, recorded live 2026-10-052026-10-09: P/E 36.6, Significantly overvalued, recalculated for the week of 2026-10-102026-10-09: P/E 36.6, Significantly overvalued, recorded live 2026-10-122026-10-16: P/E 30.6, Significantly overvalued, recalculated for the week of 2026-10-172026-10-16: P/E 30.6, Significantly overvalued, recorded live 2026-10-192026-10-23: P/E 25.8, Significantly overvalued, recalculated for the week of 2026-10-242026-10-23: P/E 25.8, Significantly overvalued, recorded live 2026-10-262026-10-30: P/E 25.1, Significantly overvalued, recalculated for the week of 2026-10-312026-10-30: P/E 25.1, Significantly overvalued, recorded live 2026-11-0220.030.0Sep 18Sep 28Oct 9Oct 20Oct 30Normal P/E 12.6
Favorable on our testsSignificantly overvaluedLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-09-19P/E 33.8+168%Favorable on our tests (recalculated)
2026-09-28P/E 37.1+194%Significantly overvalued (across a rating rules change)
2026-10-03P/E 39.5+213%Significantly overvalued (recalculated)
2026-10-31P/E 25.1+99%Significantly overvalued (recalculated)
2026-11-02P/E 25.1+99%Significantly overvalued ← now
Show all 14 readings
WeekCurrent P/EPremium to normal P/ERating
2026-09-19P/E 33.8+168%Favorable on our tests (recalculated)
2026-09-21P/E 33.8+168%Favorable on our tests
2026-09-26P/E 37.1+194%Favorable on our tests (recalculated)
2026-09-28P/E 37.1+194%Significantly overvalued (across a rating rules change)
2026-10-03P/E 39.5+213%Significantly overvalued (recalculated)
2026-10-05P/E 39.5+213%Significantly overvalued
2026-10-10P/E 36.6+190%Significantly overvalued (recalculated)
2026-10-12P/E 36.6+190%Significantly overvalued
2026-10-17P/E 30.6+143%Significantly overvalued (recalculated)
2026-10-19P/E 30.6+143%Significantly overvalued
2026-10-24P/E 25.8+104%Significantly overvalued (recalculated)
2026-10-26P/E 25.8+104%Significantly overvalued
2026-10-31P/E 25.1+99%Significantly overvalued (recalculated)
2026-11-02P/E 25.1+99%Significantly overvalued ← now

Frequently asked questions

Is Celestica stock overvalued?

At a current P/E of 19.2 versus its historical normal P/E of 12.6, Celestica trades about 52% above its typical valuation, with a PEG of 0.29 on 65.9% forward growth. tickerseer currently rates it significantly overvalued.

What is Celestica's fair value and PEG?

Celestica trades at a current P/E of 19.2 against a historical normal P/E of 12.6, a PEG of 0.29, and a forward growth estimate of 65.9%. Priced at its historical normal P/E of 12.6 on the same blended earnings, the 2026-11-06 close of $206.68 corresponds to about $136 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Celestica changed?

tickerseer's rating moved from favorable on our tests (2026-09-19) to significantly overvalued (2026-11-02). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

What is the analyst price target for Celestica?

The mean Wall Street price target for Celestica is $464.78 across 18 analysts, 124.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Contract electronics makers. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.